Legend Biotech Highlights Strong CARVYKTI® Growth, Regulatory Wins, and Path to Profitability

summarizeSummary

Legend Biotech reported strong commercial and clinical progress for CARVYKTI®, including a key label expansion, increased manufacturing, and a projected path to company-wide profitability in 2026.

check_boxKey Events

• CARVYKTI® Label Expansion

  Received U.S. Food and Drug Administration and European Commission approval to include overall survival benefit for CARVYKTI® versus standard therapies in its label, supported by data from the landmark Phase 3 CARTITUDE-4 study.

• Manufacturing Capacity Boost

  Completed physical expansion of the Raritan facility, marking the largest cell therapy manufacturing facility in the U.S. and providing installed capacity to support treatment of up to 10,000 patients annually.

• Path to Profitability

  Anticipates CARVYKTI® franchise FY 2025 profitability and expects to achieve company-wide operating profit in 2026, supported by approximately $1.0 billion in cash as of September 30, 2025.

• Clinical Milestones

  Treated over 10,000 clinical and commercial patients to date with CARVYKTI® and completed enrollment of the Phase 3 CARTITUDE-6 registrational trial in newly-diagnosed multiple myeloma patients.

auto_awesomeAnalysis

Legend Biotech provided a comprehensive business update, emphasizing significant progress with its flagship CARVYKTI® therapy, including a crucial FDA and European Commission approval for overall survival benefit in its label. The company also detailed expanded manufacturing capacity, promising pipeline advancements, and a clear financial outlook, projecting CARVYKTI® franchise profitability for FY2025 and company-wide operating profit in 2026. These updates collectively reinforce the company's market leadership and future growth potential.